First Solar (FSLR) Q1 2026: Backlog Climbs to 47.9GW as CURE Rollout Unlocks $0.6B Revenue Potential

2026-04-30 | By EarningsIQ Research

First Solar’s record Q1 and 47.9 gigawatt backlog underscore its strategic edge in both U.S. and India, while the CURE technology ramp and disciplined contracting signal a multi-year revenue unlock. Management’s focus on domestic content, IP enforcement, and selective bookings positions FSLR to capitalize on policy tailwinds and supply chain independence, but execution hinges on regulatory clarity and tariff outcomes in the coming quarters.

Summary

• CURE Technology Rollout Accelerates: CURE launch is underway, with full fleet replication targeted by 2028 to drive future revenue and margin uplift.
• Disciplined U.S. Contracting Amid Policy Uncertainty: Selective bookings and pricing discipline reflect a wait-and-see approach to Section 232 and regulatory changes.
• India and U.S. Manufacturing Anchor Growth: Domestic manufacturing and supply chain independence drive customer demand and strategic positioning.

Performance Analysis

First Solar delivered record Q1 revenue and margin expansion, driven by a 31 percent increase in module volume and strong execution in both U.S. and India markets. The U.S. segment, representing the majority of volume and margin, benefited from high utilization rates, Section 45X tax credits, and improved logistics, while India sales hit a record with 1 gigawatt delivered at attractive gross margin percentages. International operations, notably in Malaysia and Vietnam, remained underutilized due to ongoing trade and tariff headwinds, reflecting management’s cautious stance on non-U.S. production until policy clarity emerges.

Gross margin expanded by 6 points YoY, reaching 47 percent, supported by lower freight and warehousing costs and a favorable mix of modules qualifying for tax benefits. However, the average selling price (ASP) declined due to higher India mix, and tariff costs increased, partially offsetting gains. Adjusted EBITDA of $520 million exceeded the high end of guidance, while net cash finished at $2 billion, providing ample balance sheet flexibility for ongoing investment in technology, capacity, and IP enforcement.

• India Sales Mix Drives Margin Shift: High India volume contributed to lower ASP but did not materially impact gross margin percentage due to cost structure and domestic demand strength.
• Warehousing and Freight Efficiencies Materialize: Sequential $22 million reduction in warehouse costs and halved freight rates year-over-year improved margins.
• International Fleet Underutilization Persists: Malaysia and Vietnam plants operate below capacity, awaiting tariff and policy decisions before scaling output.

Management’s focus on cash discipline and cost rationalization is evident in the sequential improvement in working capital and continued investment in next-gen manufacturing, notably the South Carolina finishing facility and perovskite pilot line development.

Executive Commentary

Strategic Positioning

1. Technology Differentiation: CURE and Perovskite Roadmap

CURE, First Solar’s next-generation module platform, is positioned to deliver up to 8 percent higher lifetime energy yield versus leading competitors. The CURE launch is complete in Perrysburg and will be replicated across Series 6 and 7 lines by 2028, unlocking up to $0.6 billion in incremental revenue from technology adjusters embedded in the backlog. The company is also advancing a 1 gigawatt perovskite pilot line, targeting field validation and future cost reduction—critical for sustaining long-term technology leadership.

2. Domestic Manufacturing and Supply Chain Independence

First Solar’s U.S. manufacturing footprint, including the upcoming South Carolina finishing facility, enables the company to optimize for Section 45X tax credits, tariff mitigation, and domestic content bonuses. This strategy increases project value for customers and insulates FSLR from supply chain shocks and Chinese crystalline silicon (c-Si) dependency. In India, a similar vertically integrated approach aligns with local policy and energy security priorities, reinforcing market share in a high-growth region.

3. Selective Contracting and Policy-Driven Bookings

Management is prioritizing pricing discipline and risk allocation, especially in the U.S., by limiting new bookings until Section 232 tariff outcomes and other regulatory uncertainties are resolved. This approach preserves ASPs and positions FSLR to capitalize on pent-up demand once policy clarity emerges, with several gigawatts of potential bookings in the pipeline pending tariff decisions.

4. Intellectual Property Enforcement and Licensing

First Solar continues to defend its IP, with a Section 337 investigation underway at the U.S. International Trade Commission targeting leading importers of Topcon modules. Management is open to licensing arrangements but insists on fair value, reinforcing FSLR’s role as a technology gatekeeper as new domestic competitors, including Tesla, ramp U.S. solar manufacturing.

5. Flexible International Capacity Strategy

The company is maintaining optionality for its Malaysia and Vietnam plants, adjusting output and risk allocation based on tariff outcomes and potential demand shifts. A significant portion of Southeast Asian capacity is being repurposed to support U.S. finishing or perovskite pilot lines, reducing exposure to unfavorable international ASPs and tariffs.

Key Considerations

First Solar’s Q1 2026 demonstrates the interplay of technology, policy, and disciplined execution as the company navigates a complex regulatory and competitive landscape. Investors should weigh the following:

• CURE-Driven ASP and Margin Uplift: Full fleet rollout of CURE could materially increase future revenue and margin, particularly as technology adjusters become embedded in base pricing.
• Section 232 Tariff Decision as Booking Catalyst: A favorable policy outcome could unlock several gigawatts of pent-up U.S. demand, but adverse decisions may pressure ASPs or leave capacity underutilized.
• India Market Remains a High-Margin Outlet: Strong domestic demand and favorable policy in India provide a buffer against U.S. policy risk, though efficiency standards and local content rules are evolving.
• IP Enforcement Supports Strategic Pricing: Active litigation and willingness to license IP could limit margin erosion from new entrants and sustain pricing power in the U.S. market.
• Balance Sheet Strength Enables Flexibility: Net cash at the high end of target range supports ongoing investment in technology, manufacturing, and potential M&A or IP settlements.

Risks

Execution risk is elevated around regulatory outcomes, particularly Section 232 tariffs, which will determine the viability of international production and future U.S. bookings. Uncertainty in India’s efficiency and local content requirements could impact long-term demand. Rising domestic and global competition, as well as ongoing ASP pressure, threaten margin stability if policy tailwinds fade or if technology adoption lags expectations. IP enforcement, while a strategic asset, also introduces litigation risk and potential delays in market expansion.

Forward Outlook

For Q2 2026, First Solar guided to:

• Volume sold between 3.4 and 4 gigawatts
• Adjusted EBITDA of $400 to $500 million

For full-year 2026, management reaffirmed prior guidance, citing:

• Strong U.S. and India demand, with domestic capacity substantially committed through 2028
• Ongoing CURE rollout and anticipated technology adjuster revenue in 2027 and 2028

Management highlighted several factors that will shape the outlook:

• Pending Section 232 and other trade policy outcomes as gating items for bookings and international utilization
• Potential for incremental gross margin if tariffs are not replaced in the back half of the year

Takeaways

First Solar’s Q1 results reinforce its strategic advantage in technology and domestic manufacturing, but the next leg of growth depends on regulatory clarity and successful CURE scaling.

• Backlog and Technology Roadmap Support Multi-Year Visibility: The 47.9 GW backlog and CURE deployment provide revenue and margin tailwinds through 2028, contingent on execution.
• Policy-Driven Optionality Remains Central: Section 232 and India policy outcomes will determine the pace and profitability of both U.S. and international operations.
• Investors Should Watch for Booking Acceleration Post-Tariff Decisions: Management signals several gigawatts of demand could be unlocked quickly if policy outcomes are favorable.

Conclusion

First Solar’s record Q1, robust backlog, and disciplined strategy position it well for policy-driven upside, but the company’s next phase of growth will depend on CURE execution and regulatory clarity. Investors should focus on tariff outcomes, CURE margin realization, and IP enforcement as key drivers of future value.

Industry Read-Through

First Solar’s results highlight the growing importance of domestic manufacturing, technology differentiation, and IP enforcement in the solar supply chain. The company’s ability to command premium pricing and margin through CURE, while leveraging Section 45X and domestic content incentives, sets a template for peers seeking resilience amid global trade volatility. The emphasis on supply chain independence and regulatory engagement signals that U.S. and India solar markets will increasingly reward vertically integrated, policy-savvy players. Other module makers should anticipate intensifying IP scrutiny and the need for rapid technology refresh cycles to compete for high-value utility-scale projects.

FSLR Technology Solar Manufacturing Backlog Tariffs India Innovation